TriSalus Life Sciences, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Six months ended June 30, 2025 and 2024
(unaudited, in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss available to common stockholders | $(18,663) | $(17,538) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 337 | 369 |
| Reduction in the carrying amount of right-of-use assets | 210 | 152 |
| Change in fair value of warrants and SEPA liabilities | 1,312 | 6,921 |
| Change in fair value of OrbiMed Warrants and revenue base redemption liabilities | (147) | (426) |
| Change in fair value of contingent earnout liability | 120 | (9,701) |
| Non-cash interest expense | 584 | 151 |
| Stock-based compensation expense | 3,512 | 2,361 |
| Allowance for credit losses | 96 | — |
| Loss on disposal of property and equipment | 117 | 18 |
| Amortization of debt issuance costs | 492 | 267 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (540) | (1,152) |
| Inventory, net | 241 | (899) |
| Prepaid expenses | 777 | (2,025) |
| Deposits | — | 43 |
| Operating lease liabilities | (81) | (170) |
| Trade payables and accrued liabilities | (186) | (2,660) |
| Net cash used in operating activities | (11,819) | (24,289) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (661) | (126) |
| Proceeds from the disposal of property and equipment | 40 | — |
| Net cash used in investing activities | (621) | (126) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of common stock | 22,211 | 6,743 |
| Common stock issuance costs | (1,549) | — |
| Debt issuance costs | (520) | (2,593) |
| Proceeds from the issuance of debt | 10,000 | 25,000 |
| Payments on finance lease liabilities | (72) | (43) |
| Proceeds from the exercise of stock options for common stock | 335 | 12 |
| Net cash provided by financing activities | 30,405 | 29,119 |
| Increase in cash, cash equivalents and restricted cash | 17,965 | 4,704 |
| Cash, cash equivalents and restricted cash, beginning of period | 8,875 | 12,127 |
| Cash, cash equivalents and restricted cash, end of period | $26,840 | $16,831 |
| Supplemental disclosures of cash flow information: | ||
| Interest paid | $1,557 | $451 |
| Income taxes | $16 | $4 |
| Supplemental disclosures of non-cash items: | ||
| Prepaid warrant issuance costs | $— | $1,700 |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $— | $90 |
| Fixed asset purchase through exchange of finance lease right-of-use asset | $85 | $— |
| Derecognition of finance lease right-of-use asset | $(85) | $— |
| Fixed asset purchases included in trade payables and accrued expenses | $20 | $— |
| Fair value of warrants issued related to OrbiMed debt | $366 | $811 |
| Fair value of revenue base redemption liability related to OrbiMed debt | $— | $729 |
| Non-cash interest expense | $584 | $151 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.